2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
April 17, 2018
By: Ross Blau
Westlaw Journal
Ross Blau co-authored, "2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways" with Jonathan Harris and Drew Hillier which was published by Westlaw Journal Medical Devices, Westlaw Journal Products Liability, Westlaw Journal Health Law, Westlaw Journal Pharmaceutical and Westlaw Journal Intellectual Property. The article discusses nuanced shifts in Federal Circuit opinions and the lessons that can be gleaned from them.
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Axinn Earns Top Antitrust Rankings Coast to Coast in GCR 100
Awards & Recognitions
Why Should I Care About Property Controls?
Speaking Engagement
Antitrust
What’s the Score, Your Honor? Conversation With Judge Richard Boulware
Podcast
LCA Renaissance Symposium XIX 2025
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
Japan Competition Law Update
Axinn Viewpoints
Antitrust
